CSL (OTCMKTS:CSLLY) Shares Down 6.7% – Here’s What Happened

CSL Limited Sponsored ADR (OTCMKTS:CSLLY)’s share price traded down 6.7% during mid-day trading on Wednesday . The company traded as low as $23.05 and last traded at $23.0890. 6,939 shares changed hands during mid-day trading, a decline of 98% from the average session volume of 427,335 shares. The stock had previously closed at $24.75.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the stock. Zacks Research raised shares of CSL from a “strong sell” rating to a “hold” rating in a research report on Monday, December 29th. Royal Bank Of Canada cut shares of CSL from a “moderate buy” rating to a “hold” rating in a research report on Wednesday, February 11th. One investment analyst has rated the stock with a Strong Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy”.

CSL Stock Performance

The company’s 50-day moving average is $32.13 and its two-hundred day moving average is $51.01.

CSL Company Profile

CSL Limited (OTCMKTS: CSLLY) is a global biotechnology company headquartered in Melbourne, Australia that develops, manufactures and delivers a range of plasma-derived and recombinant therapeutics, vaccines and related services. Its principal businesses include CSL Behring, which focuses on specialty biotherapies for bleeding disorders, immune deficiencies, hereditary angioedema and other serious conditions; Seqirus, an influenza vaccine company formed following CSL’s acquisition of Novartis’ influenza vaccine business; and CSL Plasma, a network of plasma collection centers that supplies the raw material for many of its therapies.

The company’s product portfolio spans immunoglobulins, clotting factor concentrates, albumin and other protein-based treatments used in the management of chronic and acute rare diseases, as well as seasonal and pandemic influenza vaccines.